US EditionPublished • loading... • Updated
Richard Curran: Trump may not want to close the stable door after the big US pharma horse has bolted
- Concerns rise over Australia's pharmaceutical exports, worth $1.1 billion, being affected by potential US tariffs, impacting the prices of essential medicines for Australians.
- Prime Minister Anthony Albanese stated that he ruled out retaliatory tariffs on the US, emphasizing Australia remains engaged diplomatically and that such tariffs would be paid by consumers.
- Health Minister Mark Butler announced new listings on the Pharmaceutical Benefits Scheme that will provide cheaper access to treatments for women, benefiting approximately 8,500 Australians annually, addressing criticisms about delays in adding new medications.
- Warnings have emerged that US companies might attempt to alter Australia's Pharmaceutical Benefits Scheme due to trade tensions.
Insights by Ground AI
16 Articles
16 Articles
Richard Curran: Trump may not want to close the stable door after the big US pharma horse has bolted
We may yet avoid a massive financial hit to the country through tariffs on US pharmaceutical exports, despite Donald Trump placing the sector front and centre at his meeting with the Taoiseach.
·Ireland
Read Full Article
Coverage Details
Total News Sources16
Leaning Left5Leaning Right5Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
